Epilepsy in Biological Technology
Navigation Links
Epilepsy in Biological Technology
... BVA-601 trial in the Kainic acid model of epilepsy
epilepsy is a common chronic neurological disorder ... or synchronous neuronal activity in the
brain. epilepsy is one of the world's oldest recognized ...
... aimed at preventing sudden unexpected death in epilepsy (SUDEP) using its neuromodulation platform. epilepsy is the most common neurological disorder, ... stimulation product, Medtronic's Intercept(TM) epilepsy Control System, which is currently in clinical ...
... fewer seizures in adult partial-onset epilepsy patients whose seizures were inadequately ... encouraging given the number of people with epilepsy who, despite current therapies, still face the ... The mean number of years since diagnosis of epilepsy was 22.3 (+ or - 12.56 years). During the ...
... Seeks Approval for Use in epilepsy as Adjunctive Treatment in Partial Onset ... presented at the annual meeting of the American epilepsy Society later this year. In 1999, J&JPRD and SK ... About Partial Onset Seizures and Epilepsy epilepsy is one of the most common disorders of the ...
... said Steve S. Chung, Director of Clinical epilepsy Research at the Barrow Neurological Institute in Phoenix. "Approximately one third of people with epilepsy are resistant to current antiepileptic drugs. ... of lacosamide as an adjunctive treatment in epilepsy patients with partial onset seizures, finding ...
... Massey. "Rufinamide, a structurally novel compound with proven efficacy in epilepsy and with an extensive safety database, was a perfect candidate to ... anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. Eisai has also submitted an NDA for ...
... along with executives from public and private equity biotechnology companies to discuss: -- Congestive Heart Failure -- Cystic Fibrosis -- epilepsy -- Fibromyalgia -- Lung Cancer -- Neurodegenerative Diseases -- Novel Solid Tumor Targets -- Osteoporosis -- Pre-ASH Primer "With the ...
... a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain, muscle spasticity, thrombosis, epilepsy and a condition known as central sensitization, a persistent state of hypersensitivity to pain that is a core component of many pain conditions. ...
... and Brain Channel Panel(TM), which ChanTest designed to complement the FDA and ICH S7A safety guidance, as well as the Pain/Inflammation and epilepsy Channel Panels for profiling by therapeutic target. ChanTest has validated the panels against the "gold standard" manual patch clamp to ensure that ...
Vimpat(R) (lacosamide) C-V, a New Antiepileptic Drug (AED), To Be Available in U.S. Pharmacies
... dizziness, headache, diplopia, and nausea. epilepsy is a chronic neurological disorder affecting ... million people in the U.S. epilepsy can affect anyone at any time; it is a common ... of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is ...Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union
... -- - New Option for Treatment of epilepsy Patients With Partial Onset Seizures ... with or without secondary generalisation. epilepsy is one of the most common neurological diseases, ... seizures remain uncontrolled on existing epilepsy therapies and the inability to control seizures ...Marinus Pharmaceuticals Raises $20 Million in Series B Financing
... Advance Ganaxolone Program for the Treatment of epilepsy BRANFORD, Conn., April 10 /PRNewswire/ -- ... more than 35 Phase 1 and Phase 2 studies. Early epilepsy studies involved more than 100 patients and ... and adults suffering from refractory forms of epilepsy (patients who continue to have seizures despite ...... aimed at preventing sudden unexpected death in epilepsy (SUDEP) using its neuromodulation platform. epilepsy is the most common neurological disorder, ... stimulation product, Medtronic's Intercept(TM) epilepsy Control System, which is currently in clinical ...
... fewer seizures in adult partial-onset epilepsy patients whose seizures were inadequately ... encouraging given the number of people with epilepsy who, despite current therapies, still face the ... The mean number of years since diagnosis of epilepsy was 22.3 (+ or - 12.56 years). During the ...
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
... at the 62nd annual meeting of the American epilepsy Society in Seattle. "These data show that ... gap as an add-on therapy for people living with epilepsy whose partial onset seizures are not controlled," ... who participated in these trials had lived with epilepsy for an average of over 20 years and had not found ...Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM)
... phase III studies presented today at the American epilepsy Society (AES) Congress, Seattle, USA, show ... Zebinix(TM).(9),(10),(11) "The impact of epilepsy on quality of life and the development ... School of Medicine , USA and President of The epilepsy Therapy Project. "During clinical studies, ...... Seeks Approval for Use in epilepsy as Adjunctive Treatment in Partial Onset ... presented at the annual meeting of the American epilepsy Society later this year. In 1999, J&JPRD and SK ... About Partial Onset Seizures and Epilepsy epilepsy is one of the most common disorders of the ...
Video: Keppra XR(TM) Approved in the U.S.
... and minimal side effects. While many people with epilepsy are successfully treated with one or more of the ... at 1-866-822-0068 (press 9). About Epilepsy epilepsy is a chronic neurological disorder affecting ... of the nerve cells, or neurons, in the brain. epilepsy is characterized by a tendency to have recurrent ...Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
... for ganaxolone, an adult and pediatric epilepsy candidate in Phase II, and chelerythrine, a ... lead compound, ganaxolone, a new class of epilepsy treatment," said Stephen Bloch, chair of the ... IIb clinical trial as a potential treatment of epilepsy in children (infantile spasms) and ...Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
... epilepsy Growth of 14% Fiscal 2009 ... per share. -- Unit sales attributable to the epilepsy indication increased globally by an estimated ... product sales in fiscal 2008 attributable to the epilepsy indication were $115.3 million, an increase of ...US FDA Grants Pediatric Exclusivity for UCB's Keppra(R)
... on January 14, 2009. About Epilepsy: epilepsy is a chronic neurological disorder affecting 40 ... of the nerve cells or neurons in the brain. epilepsy is characterized by a tendency to have recurrent ... seizures in adults with juvenile myoclonic epilepsy and partial onset seizures in adults with ...Synosia Starts Phase II Efficacy Trial For Rufinamide
... epilepsy Drug to be Tested as Treatment for Anxiety ... Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient years of exposure ...Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
... is needed when dealing with complex intractable epilepsy cases," Singh continued. "The Nebraska Medical ... new hope and opportunities to people with epilepsy with a multi-phase monitoring and treatment ... us to deal with the most difficult to treat epilepsy patients, many of whom do not respond well to ...... said Steve S. Chung, Director of Clinical epilepsy Research at the Barrow Neurological Institute in Phoenix. "Approximately one third of people with epilepsy are resistant to current antiepileptic drugs. ... of lacosamide as an adjunctive treatment in epilepsy patients with partial onset seizures, finding ...
Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
... volunteers and patients in more than 35 Phase 1 and Phase 2 studies. Early epilepsy studies involved more than 250 patients and generated data supportive of ... in the treatment of both children and adults suffering from refractory epilepsy (patients who continue to have seizures despite taking multiple ...First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
... scanner already has proven successful in better characterizing partial epilepsy and nasopharyngeal cancer. Eventually, the technology could be used to ... the technology's clinical significance in patients suffering from partial epilepsy and nasopharyngeal cancera relatively rare form of cancer that develops at ...Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
... represent expenditures on Amarin's two Parkinson's disease programs, its epilepsy and memory programs and the initiation of its new cardiovascular disease ... programs in myasthenia gravis, Huntington's disease, Parkinson's disease, epilepsy and memory. Amarin also has two proprietary technology platforms: a ...... Massey. "Rufinamide, a structurally novel compound with proven efficacy in epilepsy and with an extensive safety database, was a perfect candidate to ... anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. Eisai has also submitted an NDA for ...
Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
... impairment (AAMI) now in a Phase II study and both nasal lorazepam for epilepsy seizures and AMR103 for Parkinson's disease successfully advanced in ... trial underway IIa trial ethyl-EPA) Nasal lorazepam epilepsy - Preclinical - File IND proof ...Nanotech particles affect brain development in mice
... According to Takeda, "Diseases associated with these genes include those we normally consider to develop in childhood, such as autistic disorder, epilepsy and learning disorders, and also others that arise mainly in adulthood or old age, such as Alzheimer's disease, schizophrenia and Parkinson's ....Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System
... facilitate development of new clinical therapies with the potential to improve diagnosis and treatment of a wide range of brain disorders including epilepsy and Parkinson's disease. The NeuroPort System is uniquely capable of monitoring from as many as 256 channels, with the potential to be scalable to ...Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
... platform for hypometabolism, Neuera is developing drugs for Parkinson's disease, Huntington's disease, and other neurological conditions such as epilepsy and traumatic brain injury. For more information about Accera or Neuera, please visit www.accerapharma.com . Contacts: ...Cyberonics Provides Business Update on Depression Clinical Trial
... The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the ...... along with executives from public and private equity biotechnology companies to discuss: -- Congestive Heart Failure -- Cystic Fibrosis -- epilepsy -- Fibromyalgia -- Lung Cancer -- Neurodegenerative Diseases -- Novel Solid Tumor Targets -- Osteoporosis -- Pre-ASH Primer "With the ...
... a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain, muscle spasticity, thrombosis, epilepsy and a condition known as central sensitization, a persistent state of hypersensitivity to pain that is a core component of many pain conditions. ...
$425 Million Cephalon Civil Settlement and Criminal Fine; In America's Largest
... flouted federal regulations on a grand scale for years by off-label marketing its first three prescription drugs far beyond the cancer pain, epilepsy and narcolepsy specialists for whose patients those drugs had been FDA-approved. Instead, Cephalon focused its national marketing muscle on ...Cyberonics Provides Update on Business Operations Following Hurricane Ike
... The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the ...Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
... Inc., focuses exclusively on providing solutions that improve neurological health. The company currently markets products for Alzheimer's disease, epilepsy and acute and preventative migraine treatment. Ortho-McNeil Neurologics, in conjunction with internal and external research partners, continues to ...Amarin Announces Completion of the First Tranche of $60 Million Private Placement
... acids in cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease, epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through ...Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
... than medications currently on the market because they aim to modify and treat the underlying causes, as opposed to just the symptoms, of Alzheimer's, epilepsy and various types of cancer. Prior to joining ANAVEX, Dr. Goundis spent six years in various management roles with his most recent as Managing ...D-Pharm Secures Funding From Israel's Chief Scientist's Office
... technological incubator. The CSO's backing has helped us to build a robust pipeline with two advanced clinical stage products in stroke (DP-b99) and epilepsy and migraine (DP-VPA) followed by an exciting range of preclinical developments in Alzheimer's disease, cancer and psoriasis". D-Pharm's ...... and Brain Channel Panel(TM), which ChanTest designed to complement the FDA and ICH S7A safety guidance, as well as the Pain/Inflammation and epilepsy Channel Panels for profiling by therapeutic target. ChanTest has validated the panels against the "gold standard" manual patch clamp to ensure that ...
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
... lab in the state," says Elizabeth Ragalie, Director of the Neurosciences Center at Froedtert Hospital. "We intend to use the MEG in our epilepsy program as a powerful new tool for pre-surgical planning. The non-invasive and fast measurement capability of the technology is well suited to the ...Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
... JZP-8. -- A single dose pharmacokinetic study of a controlled-release formulation of JZP-4, a product candidate for the treatment of partial epilepsy and bipolar disorder, was completed in the fourth quarter of 2007, and Phase II clinical trial activities are underway. Jazz ...Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
... of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes two programs in Parkinson's disease, one in epilepsy and one in memory and cognition. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known ...Amarin Announces Initiation of Cardiovascular Development Strategy
... of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes two programs in Parkinson's disease, one in epilepsy and one in memory and cognition. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known ...Amarin to Present at 4th Annual Bio Investor Forum
... of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes two programs in Parkinson's disease, one in epilepsy and one in memory and cognition. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known ...Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
... specialty pharma company. Prior to joining Avera, Dr. Siffert held positions with Pfizer as the worldwide medical team leader in areas of pain and epilepsy of various products including Relpax, Lyrica and Neurontin. He was also instrumental in the Phase 3b/4 program development and global launch of ...Other ContentsrespirationrespirationrespirationrespirationrespirationrespirationreversereversereversereversereversereversereversereversereverseretrovirusretrovirusretrovirusretrovirustypetypetypetypetypetypetypetypetypetypepolymorphismpolymorphismpolymorphismpolymorphismlengthlengthlengthlengthlengthlengthlengthlengthlengthfragmentfragmentfragmentfragmentfragmentfragmentfragmentfragmentrestrictionrestrictionrestrictionrestrictionrestrictionrestrictionrestrictionrestrictionOther TagsTibetComplaintsPrestigiousSpicesMalfunctionStrange
(Date:12/16/2009)... Dec. 3 BIO-key International, Inc. ... wireless public safety and finger-based biometric identification ... shareholders at a Special Shareholder Meeting held ... Law Enforcement Division to Interact911 Mobile Systems ... cast in favor and 1.2% were opposed. ...
(Date:12/16/2009)... National Instruments (Nasdaq: NATI ... control, and DENSO Robotics, a leader and ... today announced their collaboration to integrate NI ... arms. The collaboration increases productivity and performance ... applications. In today,s trend toward high-mix, low-volume ...
(Date:12/16/2009)... FALLS CHURCH, Va., Dec. 9 ... today that the American Association for Laboratory ... Electrotechnical Commission (ISO/IEC) 17025:2005 accreditation to the ... the CSC Identity Labs located in Fairmont, ... biometrics test laboratory in the world to ...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 1Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 2Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 3Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 4Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 5Clean Hands Report Card 28R 29 3A Americans Get a B on Hand Hygiene 57783 1Clean Hands Report Card 28R 29 3A Americans Get a B on Hand Hygiene 57783 2Clean Hands Report Card 28R 29 3A Americans Get a B on Hand Hygiene 57783 3A Dementia That Afflicts Younger Population Has Similarities to Alzheimers Applicable Treatments 57781 1A Dementia That Afflicts Younger Population Has Similarities to Alzheimers Applicable Treatments 57781 2A Dementia That Afflicts Younger Population Has Similarities to Alzheimers Applicable Treatments 57781 3A Dementia That Afflicts Younger Population Has Similarities to Alzheimers Applicable Treatments 57781 4(Date:12/16/2009)... is long-term goal, researchers say , , WEDNESDAY, Dec. ... to predict whether a patient will suffer a second ... "This is an important new tool because studies have ... after a first stroke are more likely to die ... General Hospital and Harvard Medical School, said in an ...
(Date:12/16/2009)... Institute announce the first comprehensive analyses of cancer genomes. ... the DNA of cancer cells which are acquired during ... and a lung cancer, reveal for the first time ... cancers. , Lung cancer causes around one million deaths ... The number of mutations found suggest that a typical ...
(Date:12/16/2009)... essential fatty acids commonly found in fatty fish ... to research published by the American Psychological Association. ... problems found in people with schizophrenia; bipolar, obsessive-compulsive, ... afflictions of the nervous system. , The ... , provides more evidence that fish is brain ...
(Date:12/16/2009)... half, but use in humans is still far off , , ... nature, researchers have built and tested synthetic versions of the ... other cases where blood just won,t stop flowing. , "We ... in degradable stitches, which dissolve in the body," said Erin ... Reserve University, and lead author of a report published ...
(Date:12/16/2009)... Specific Neurological Stress Reduction Therapy or NSRTSM is found very ... conditions such as allergies, asthma, migraines, chronic fatigue and a ... throughout the country are using this holistic therapy including over ... ... Minneapolis, MN (Vocus) December 14, 2009 -- ...
Breaking Medicine News(10 mins):Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5ChirpsShangaiManicStrainedTibetComplaintsPrestigiousSpicesMalfunctionVictorianJalgaonStrangeIntrahepaticSubstituting
Other Tagslayer 2layer 3layer 4layer 5layer 6layer 7pure 2pure 3business 2business 3replicating 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |